ArticleHealth policy and planning2024
The process of ratifying the treaty to establish the African Medicines Agency: perspectives of national regulatory agencies.
Article in Health policy and planning, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmaceutical regulatory harmonization in Africa: a scoping review of policy design, implementation approaches, and outcomes.Frontiers in medicine · 2026Pooled it
- Neuropsychiatry genetics in Africa.Nature communications · 2026Review
- Regulatory fragmentation as the hidden barrier to regional vaccine sovereignty.Nature medicine · 2026Article
- Actionable Pharmacogenomics and Essential Medicines: An Analysis of WHO and African Lists for Safer and Efficacious Drug Use.Clinical pharmacology and therapeutics · 2026Review
- Tackling Antimicrobial Resistance in the WHO African Region: Progress, Challenges, and Strategic Priorities for the Future.Health services insights · 2026Article
- Navigating the human gene editing scene and proposing a new governance framework in Africa: from knowledge to policy to action.Frontiers in genome editing · 2026Article
- Performance analysis of EAC joint GMP inspections (2016-2022): a pathway to strengthening regulatory systems and building capacity in Africa's less resourced authorities.Frontiers in medicine · 2025Article
- The African Medicines Agency - A potential gamechanger that requires strategic focus.PLOS global public health · 2025Article
- The need to update Ethiopia's national health and medicine policies: essential tools for informed decision-making in healthcare and the pharmaceutical sectors.Frontiers in public health · 2025Article
- The African Medicines Agency and Medicines Regulation: Progress, challenges, and recommendations.Health care science · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The vision of the African Medicines Agency (AMA) is to ensure that all Africans have access to affordable medical products that meet internationally recognized standards of quality, safety and efficacy for priority diseases/conditions. The AMA is being established by a treaty which had to be ratified by a minimum of 15 African countries. Although there was no deadline, the ratification process has been slower than expected. This study therefore analysed the rationale, perceived benefits, enabling factors and challenges of the AMA's establishment. This study was a qualitative, cross-sectional, census survey of the national medicines regulatory authorities (NRAs) of 45 African countries. The Heads of NRAs and a senior NRA staff member were contacted to complete self-administered questionnaires. The existence of mature NRAs, the desire to have harmonized regulatory systems, the presence of strong political will and appropriate advocacy to expedite treaty signing are all enabling factors for AMA treaty signing. The challenges reported include the fact that the process is slow and there is limited understanding of the process. Competing national priorities, changes in office bearers in the public system and stagnation of the process at the ministerial level were also challenges reported. This study has improved the understanding of the treaty signing and ratification process and the perceived benefits and enabling factors of signing and ratification from African NRAs' perspective. NRAs also highlighted challenges encountered in the process. Addressing these challenges will result in effective medicines regulation by galvanizing technical support, regulatory expertise and resources at a continental level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.